Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.49 |
| ▸ | FEN1 | P39748 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654882 | 0.92 | ALOX5AP (0.50) | ALOX5APFEN1GPR119F2RL3 | |
| SCHEMBL4666689 | 0.89 | ALOX5AP (0.51) | ALOX5APFEN1CHRNB4CHRNA3 | |
| SCHEMBL9900728 | 0.89 | ALOX5AP (0.51) | ALOX5APFEN1CHRNB4CHRNA3 | |
| SCHEMBL9241908 | 0.89 | ALOX5AP (0.51) | ALOX5APFEN1CHRNB4CHRNA3 | |
| SCHEMBL4328668 | 0.86 | ALOX5AP (0.50) | ALOX5APFEN1GPR119 | |
| SCHEMBL4328662 | 0.86 | ALOX5AP (0.50) | ALOX5APFEN1GPR119 | |
| SCHEMBL9243394 | 0.85 | ALOX5AP (0.51) | ALOX5APFEN1GPR119APPHTR1A | |
| SCHEMBL2201811 | 0.85 | ALOX5AP (0.51) | ALOX5APFEN1GPR119APPHTR1A | |
| SCHEMBL9243387 | 0.85 | ALOX5AP (0.51) | ALOX5APFEN1GPR119APPHTR1A | |
| SCHEMBL938053 | 0.83 | ABHD6 (0.50) | ALOX5APFEN1GPR119CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367816-B1 | ISATIN DERIVATIVES FOR USE AS IN VIVO IMAGING AGENTS | IMP INNOVATIONS LTD (GB) | 2016-11-09 | — | — | EP | disclosed |
| US-8961930-B2 | Isatin derivatives for use as in vivo imaging agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| EP-2367816-A1 | ISATIN DERIVATIVES FOR USE AS IN VIVO IMAGING AGENTS | Imperial Innovations Limited (GB) | 2011-09-28 | — | — | EP | disclosed |
| US-20110195024-A1 | ISATIN DERIVATIVES FOR USE AS IN VIVO IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| WO-2010026388-A1 | ISATIN DERIVATIVES FOR USE AS IN VIVO IMAGING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2010-03-11 | — | — | WO | disclosed |
| US-5472958-A | 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function | ABBOTT LABORATORIES (US) | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195024-A1 | ISATIN DERIVATIVES FOR USE AS IN VIVO IMAGING AGENTS | CASP5, CASP3, CASP14 | ALOX5AP 633/4885FEN1 2355/4885GPR119 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.